Juergen Funk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Juergen Funk has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Zeller
RED Innovation Center Basel, F. Hoffmann-La Roche Ltd Pharmaceutical Sciences Grenzacherstrasse 124, Basel, CH-4070
2 shared publications - Carole L. Yauk
Department of Biology, University of Ottawa
2 shared publications - Danielle P. M. LeBlanc
Health Canada, Ottawa, ON, Canada
2 shared publications - Fangyao Hu
Genentech Inc, South San Francisco, California, USA
2 shared publications - Fernando Romero-Palomo
Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland
2 shared publications - Francesco Marchetti
Health Canada
2 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by Elsevier in SSRN Electronic Journal
Prolonged Benzo[b]fluoranthene Exposure Increases Tissue-Specific Mutational Burden, Expansion of Mutant Cells, and Mutagenic Potency
Chronic exposure to polycyclic aromatic hydrocarbons (PAHs) is associated with increased risk of cancer through a mutagenic mode of action. We investigated how exposure duration influences mutagenicity in bone marrow (BM) and liver of MutaMouse males orally exposed to increasing doses of benzo[b]fluoranthene (BbF), a priority PAH, for 28, 90, or 180 days. We applied Duplex Sequencing (DS) across 20 endogenous loci to assess dose- and time-dependent effects on mutation frequency, clonal expansion of mutant cells, mutation distribution, and spectra. Mutation frequencies increased with BbF dose and exposure duration in both tissues. After 90 and 180 days of exposure to 25 mg/kg/day BbF, mutation frequency was 1.8x and 2.4x higher in BM, and 3.8x and 8.6x higher in liver, than 28-day exposures. Clonally derived mutations increased significantly with exposure duration in BM but not liver. Intergenic loci incurred more mutations than genic regions in both tissues across all exposure durations. Mutation spectra were dominated by C:G>A:T transversions and was enriched in SBS4, the mutation signature associated with tobacco-induced human lung cancer. Benchmark dose (BMD50) modeling showed increasing BbF potency with longer exposures. BMD50 decreased from 8.2 (28d) to 3.7 (90d) and 3.0 (180d) mg/kg/day in BM; in liver, BMD50 shifted from 14.3 (28d) to 4.3 (90d) and 3.9 (180d) mg/kg/day. The observed tissue-specific responses may be attributed to differences in proliferation rate, metabolic activity, and cellular lifespan. Our findings provide insights into the mutagenic impacts of prolonged PAH exposure and highlight tissue-specific differences in mutation susceptibility.
- 9 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessProlonged Benzo[b]fluoranthene Exposure Increases Tissue-Specific Mutational Burden, Expansion of Mutant Cells, and Mutagenic Potency
Chronic exposure to polycyclic aromatic hydrocarbons (PAHs) is associated with increased risk of cancer through a mutagenic mode of action. We investigated how exposure duration influences mutagenicity in bone marrow (BM) and liver of MutaMouse males orally exposed to increasing doses of benzo[b]fluoranthene (BbF), a priority PAH, for 28, 90, or 180 days. We applied Duplex Sequencing (DS) across 20 endogenous loci to assess dose- and time-dependent effects on mutation frequency, clonal expansion of mutant cells, mutation distribution, and spectra. Mutation frequencies increased with BbF dose and exposure duration in both tissues. After 90 and 180 days of exposure to 25 mg/kg/day BbF, mutation frequency was 1.8x and 2.4x higher in BM, and 3.8x and 8.6x higher in liver, than 28-day exposures. Clonally derived mutations increased significantly with exposure duration in BM but not liver. Intergenic loci incurred more mutations than genic regions in both tissues across all exposure durations. Mutation spectra were dominated by C:G>A:T transversions and was enriched in SBS4, the mutation signature associated with tobacco-induced human lung cancer. Benchmark dose (BMD50) modeling showed increasing BbF potency with longer exposures. BMD50 decreased from 8.2 (28d) to 3.7 (90d) and 3.0 (180d) mg/kg/day in BM; in liver, BMD50 shifted from 14.3 (28d) to 4.3 (90d) and 3.9 (180d) mg/kg/day. The observed tissue-specific responses may be attributed to differences in proliferation rate, metabolic activity, and cellular lifespan. Our findings provide insights into the mutagenic impacts of prolonged PAH exposure and highlight tissue-specific differences in mutation susceptibility.
- Open Access
- 10 March 2026
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 209 (3)
Expansion of preexisting cancer driver mutant clones is induced by the genotoxic carcinogen benzo[b]fluoranthene in MutaMouse lung
Clonal expansion (CE) of cells carrying cancer driver mutations (CDMs) is being developed as a biomarker of cancer risk. CE in lung of MutaMouse males treated with 0, 6.25, 12.5, and 25 mg/kg/day benzo[b]fluoranthene (B[b]F) by gavage for 90 and 180 days was assessed by CarcSeq. DNA regions encompassing mouse correlates of human hotspot CDMs were PCR amplified, attaching 18-base unique molecular identifiers (UMIs) during the PCR. Following library preparation and sequencing, UMI-defined read families were assembled to produce single-strand consensus sequences (SSCSs). Recovered mutants with mutant fractions (MFs) ≥10−4 were stratified based on their occurrence in lung-specific or non-lung driver sequences and CE was assessed on a per mouse basis as median absolute deviation in mutant fraction (MAD). A significant, dose-dependent increase in MAD was observed for lung-specific MFs after 180 days of B[b]F treatment, a duration that did not cause a significant increase in lung lesions. Dose and treatment duration related increases in MF were observed for Egfr, the mouse correlate of a known human lung tumor driver gene. MF and mutation counts were significantly decreased in response to longer treatment duration for some non-lung drivers, suggesting negative selection. Importantly, the normalized trinucleotide mutation spectrum derived from CDMs reflects amplification of preexisting spontaneous mutations, distinct from those induced by B[b]F mutagenesis. These results show CarcSeq detects CE of preexisting cancer driver gene mutants induced by the genotoxic carcinogen B[b]F and suggests a CE endpoint may be useful for evaluating cancer risk associated with tumor promoters or complete carcinogens.
- 10 March 2026
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 209 (3)
Open AccessExpansion of preexisting cancer driver mutant clones is induced by the genotoxic carcinogen benzo[b]fluoranthene in MutaMouse lung
Clonal expansion (CE) of cells carrying cancer driver mutations (CDMs) is being developed as a biomarker of cancer risk. CE in lung of MutaMouse males treated with 0, 6.25, 12.5, and 25 mg/kg/day benzo[b]fluoranthene (B[b]F) by gavage for 90 and 180 days was assessed by CarcSeq. DNA regions encompassing mouse correlates of human hotspot CDMs were PCR amplified, attaching 18-base unique molecular identifiers (UMIs) during the PCR. Following library preparation and sequencing, UMI-defined read families were assembled to produce single-strand consensus sequences (SSCSs). Recovered mutants with mutant fractions (MFs) ≥10−4 were stratified based on their occurrence in lung-specific or non-lung driver sequences and CE was assessed on a per mouse basis as median absolute deviation in mutant fraction (MAD). A significant, dose-dependent increase in MAD was observed for lung-specific MFs after 180 days of B[b]F treatment, a duration that did not cause a significant increase in lung lesions. Dose and treatment duration related increases in MF were observed for Egfr, the mouse correlate of a known human lung tumor driver gene. MF and mutation counts were significantly decreased in response to longer treatment duration for some non-lung drivers, suggesting negative selection. Importantly, the normalized trinucleotide mutation spectrum derived from CDMs reflects amplification of preexisting spontaneous mutations, distinct from those induced by B[b]F mutagenesis. These results show CarcSeq detects CE of preexisting cancer driver gene mutants induced by the genotoxic carcinogen B[b]F and suggests a CE endpoint may be useful for evaluating cancer risk associated with tumor promoters or complete carcinogens.
- 30 May 2025
- Published by SAGE Publications in Toxicologic Pathology
Comparison of an Attention-Based Multiple Instance Learning (MIL) With a Visual Transformer Model: Two Weakly Supervised Deep Learning (DL) Algorithms for the Detection of Histopathologic Lesions in the Rat Liver to Distinguish Normal From Abnormal
The histopathologic evaluation of regulatory toxicity studies using artificial intelligence (AI) has the potential to increase study efficiency. For example, AI could initially identify and exclude all organs without histopathologic lesions, allowing pathologists to focus solely on evaluating organs with identified lesions. In this study, whole slide images (WSIs) of liver sections from 58 different rat toxicity studies were collected, along with their corresponding histopathologic lesion diagnoses. Each WSI was labeled as either “lesion” or “no lesion” based on the presence or absence of reported histopathologic lesions. Multiple instance learning (MIL) approaches, including a transformer variant, were tested to predict lesions within a weakly supervised framework. Both methods achieved acceptable to excellent area under the receiver operating characteristic curve (AUROC) scores. Heatmap overlays were employed to visually assess the MIL model’s effectiveness in detecting lesions, confirming the accuracy of targeted areas on the WSIs. In addition, using transfer learning principles, the MIL model initially developed for liver WSIs was adapted to kidney WSIs, demonstrating the model’s versatility. This study showcases the application of weakly supervised learning for lesion detection in rat WSIs from toxicity studies, with the potential to significantly enhance the efficiency of the histopathologic evaluation process.
- 30 May 2025
- Published by SAGE Publications in Toxicologic Pathology
Comparison of an Attention-Based Multiple Instance Learning (MIL) With a Visual Transformer Model: Two Weakly Supervised Deep Learning (DL) Algorithms for the Detection of Histopathologic Lesions in the Rat Liver to Distinguish Normal From Abnormal
The histopathologic evaluation of regulatory toxicity studies using artificial intelligence (AI) has the potential to increase study efficiency. For example, AI could initially identify and exclude all organs without histopathologic lesions, allowing pathologists to focus solely on evaluating organs with identified lesions. In this study, whole slide images (WSIs) of liver sections from 58 different rat toxicity studies were collected, along with their corresponding histopathologic lesion diagnoses. Each WSI was labeled as either “lesion” or “no lesion” based on the presence or absence of reported histopathologic lesions. Multiple instance learning (MIL) approaches, including a transformer variant, were tested to predict lesions within a weakly supervised framework. Both methods achieved acceptable to excellent area under the receiver operating characteristic curve (AUROC) scores. Heatmap overlays were employed to visually assess the MIL model’s effectiveness in detecting lesions, confirming the accuracy of targeted areas on the WSIs. In addition, using transfer learning principles, the MIL model initially developed for liver WSIs was adapted to kidney WSIs, demonstrating the model’s versatility. This study showcases the application of weakly supervised learning for lesion detection in rat WSIs from toxicity studies, with the potential to significantly enhance the efficiency of the histopathologic evaluation process.
- 5 November 2022
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 50 (8) , 942-949
Toxicologic Pathology Forum: A Roadmap for Building State-of-the-Art Digital Image Data Resources for Toxicologic Pathology in the Pharmaceutical Industry
Digitization of histologic slides brings with it the promise of enhanced toxicologic pathology practice through the increased application of computational methods. However, the development of these advanced methods requires access to substrate image data, that is, whole slide images (WSIs). Deep learning methods, in particular, rely on extensive training data to develop robust algorithms. As a result, pharmaceutical companies interested in leveraging computational methods in their digital pathology workflows must first invest in data infrastructure to enable data access for both data scientists and pathologists. The process of building robust image data resources is challenging and includes considerations of generation, curation, and storage of WSI files, and WSI access including via linked metadata. This opinion piece describes the collective experience of building resources for WSI data in the Roche group. We elaborate on the challenges encountered and solutions developed with the goal of providing examples of how to build a data resource for digital pathology analytics in the pharmaceutical industry.
- 5 November 2022
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 50 (8) , 942-949
Toxicologic Pathology Forum: A Roadmap for Building State-of-the-Art Digital Image Data Resources for Toxicologic Pathology in the Pharmaceutical Industry
Digitization of histologic slides brings with it the promise of enhanced toxicologic pathology practice through the increased application of computational methods. However, the development of these advanced methods requires access to substrate image data, that is, whole slide images (WSIs). Deep learning methods, in particular, rely on extensive training data to develop robust algorithms. As a result, pharmaceutical companies interested in leveraging computational methods in their digital pathology workflows must first invest in data infrastructure to enable data access for both data scientists and pathologists. The process of building robust image data resources is challenging and includes considerations of generation, curation, and storage of WSI files, and WSI access including via linked metadata. This opinion piece describes the collective experience of building resources for WSI data in the Roche group. We elaborate on the challenges encountered and solutions developed with the goal of providing examples of how to build a data resource for digital pathology analytics in the pharmaceutical industry.
- 23 March 2022
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 50 (3) , 308-328
Immunohistochemical Characterization of Proliferative Lesions in the Thymus of Aging CD-1 Mice From Two Studies on the RITA Database, With Special Reference to the Perivascular Space
Thymic lymphoid hyperplasia is a common age-related finding, which occurs particularly in female CD-1 mice. The main differential diagnoses are malignant lymphoma and thymoma. A systematic investigation of control groups from two carcinogenicity studies was performed including measurements of thymic size, and the immunohistochemistry (IHC) markers pan-Cytokeratin (pan-CK) for thymic epithelial cells; CD3 and CD45R/B220 for T and B lymphocytes, respectively; CD31 for endothelial cells; and F4/80 for macrophages. Thymoma can be differentiated by increased numbers of proliferating epithelial cells demonstrated by pan-CK IHC staining. Differentiation between lymphoid hyperplasia and lymphoma is more challenging as a mixture of B and T lymphocytes can be present in both findings. The present investigation showed that the thymic perivascular space is the compartment where the increased numbers of lymphocytes in hyperplasia are localized and not the medulla, as previously thought. The lymphoepithelial compartment is atrophic to the same extent in thymi diagnosed with age-related involution or lymphoid hyperplasia. Both diagnoses are thus related to variations in lymphoid cellularity of the nonepithelial perivascular space, which is continuous with the perithymic tissue. Likewise, lymphomas have a predilection to colonize the perivascular space and to spare the lymphoepithelial compartment.
- 23 March 2022
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 50 (3) , 308-328
Immunohistochemical Characterization of Proliferative Lesions in the Thymus of Aging CD-1 Mice From Two Studies on the RITA Database, With Special Reference to the Perivascular Space
Thymic lymphoid hyperplasia is a common age-related finding, which occurs particularly in female CD-1 mice. The main differential diagnoses are malignant lymphoma and thymoma. A systematic investigation of control groups from two carcinogenicity studies was performed including measurements of thymic size, and the immunohistochemistry (IHC) markers pan-Cytokeratin (pan-CK) for thymic epithelial cells; CD3 and CD45R/B220 for T and B lymphocytes, respectively; CD31 for endothelial cells; and F4/80 for macrophages. Thymoma can be differentiated by increased numbers of proliferating epithelial cells demonstrated by pan-CK IHC staining. Differentiation between lymphoid hyperplasia and lymphoma is more challenging as a mixture of B and T lymphocytes can be present in both findings. The present investigation showed that the thymic perivascular space is the compartment where the increased numbers of lymphocytes in hyperplasia are localized and not the medulla, as previously thought. The lymphoepithelial compartment is atrophic to the same extent in thymi diagnosed with age-related involution or lymphoid hyperplasia. Both diagnoses are thus related to variations in lymphoid cellularity of the nonepithelial perivascular space, which is continuous with the perithymic tissue. Likewise, lymphomas have a predilection to colonize the perivascular space and to spare the lymphoepithelial compartment.
- 1 March 2017
- Published by Elsevier in Toxicology
- Vol. 379, 48-61
Use of early phenotypic in vivo markers to assess human relevance of an unusual rodent non-genotoxic carcinogen in vitro
- 1 March 2017
- Published by Elsevier in Toxicology
- Vol. 379, 48-61
Use of early phenotypic in vivo markers to assess human relevance of an unusual rodent non-genotoxic carcinogen in vitro
- 15 December 2015
- Published by Springer Nature in Histochemistry and Cell Biology
- Vol. 145 (3) , 315-326
Semiautomated quantitative image analysis of glomerular immunohistochemistry markers desmin, vimentin, podocin, synaptopodin and WT-1 in acute and chronic rat kidney disease models
Five different glomerular immunohistochemistry markers were evaluated and compared in four different acute and chronic rat kidney disease models. Progression of glomerular or podocyte damage was shown in the puromycin aminonucleoside nephrosis (PAN) and Zucker fatty/spontaneously hypertensive heart failure F1 hybrid (ZSF1) rat model. Progression and prevention of glomerular damage was demonstrated in the Zucker diabetic fatty (ZDF) and Dahl salt-sensitive (Dahl SS) rat. Immunohistochemistry was performed for desmin, vimentin, podocin, synaptopodin and Wilms tumor protein-1 (WT-1), and evaluation of glomerular immunohistochemistry markers was done by semiautomated quantitative image analysis. We found desmin and WT-1 as the most sensitive markers for podocyte damage in both acute and chronic glomerular damage followed by vimentin, podocin and synaptopodin. We were able to demonstrate that early podocyte damage as shown by increased desmin and vimentin staining together with either a phenotypic podocyte change or podocyte loss (reduced numbers of WT-1-stained podocytes) drives the progression of glomerular damage. This is followed by a reduction in podocyte-specific proteins such as podocin and synaptopodin. Our report describes the different sensitivity of glomerular or podocyte markers and gives future guidance for the selection of the most sensitive markers for efficacy testing of new drugs as well as for the selection of tissue-based toxicity markers for glomerular or podocyte injury. In addition to functional clinical chemistry markers, desmin and WT-1 immunohistochemistry offers reliable and valuable data on the morphologic state of podocytes.
- 15 December 2015
- Published by Springer Nature in Histochemistry and Cell Biology
- Vol. 145 (3) , 315-326
Semiautomated quantitative image analysis of glomerular immunohistochemistry markers desmin, vimentin, podocin, synaptopodin and WT-1 in acute and chronic rat kidney disease models
Five different glomerular immunohistochemistry markers were evaluated and compared in four different acute and chronic rat kidney disease models. Progression of glomerular or podocyte damage was shown in the puromycin aminonucleoside nephrosis (PAN) and Zucker fatty/spontaneously hypertensive heart failure F1 hybrid (ZSF1) rat model. Progression and prevention of glomerular damage was demonstrated in the Zucker diabetic fatty (ZDF) and Dahl salt-sensitive (Dahl SS) rat. Immunohistochemistry was performed for desmin, vimentin, podocin, synaptopodin and Wilms tumor protein-1 (WT-1), and evaluation of glomerular immunohistochemistry markers was done by semiautomated quantitative image analysis. We found desmin and WT-1 as the most sensitive markers for podocyte damage in both acute and chronic glomerular damage followed by vimentin, podocin and synaptopodin. We were able to demonstrate that early podocyte damage as shown by increased desmin and vimentin staining together with either a phenotypic podocyte change or podocyte loss (reduced numbers of WT-1-stained podocytes) drives the progression of glomerular damage. This is followed by a reduction in podocyte-specific proteins such as podocin and synaptopodin. Our report describes the different sensitivity of glomerular or podocyte markers and gives future guidance for the selection of the most sensitive markers for efficacy testing of new drugs as well as for the selection of tissue-based toxicity markers for glomerular or podocyte injury. In addition to functional clinical chemistry markers, desmin and WT-1 immunohistochemistry offers reliable and valuable data on the morphologic state of podocytes.
- 1 August 2005
- Published by Elsevier in Experimental and Toxicologic Pathology
- Vol. 57 (1) , 29-38
Histopathologic findings after treatment with different oxidosqualene cyclase (OSC) inhibitors in hamsters and dogs
- 1 August 2005
- Published by Elsevier in Experimental and Toxicologic Pathology
- Vol. 57 (1) , 29-38
Histopathologic findings after treatment with different oxidosqualene cyclase (OSC) inhibitors in hamsters and dogs
- 2 September 2004
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 54 (1) , 87-92
Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms
To investigate natural killer (NK) and lymphokine-activated killer (LAK) cell functions from 10 healthy dogs and 29 dogs with a variety of spontaneous neoplasms, large granular lymphocytes (LGLs) from blood samples were separated by a 58.5% Percoll density gradient. LGLs were stimulated with a low dose of recombinant human interleukin 2 (rhIL-2) for 7 days. Cytotoxicity of effector cells against the susceptible CTAC cell line was measured before and after stimulation. Compared with those before stimulation, the percentage of LGLs after stimulation with rhIL-2 was found to be significantly increased (PP<0.01) when compared with controls. Reduced cytotoxicity of rhIL-2–activated NK cells in dogs with tumors seems to be attributable to the presence of a diminished proliferative capacity of NK cells and a decreased ability of LAK cells to lyse target cells. Further knowledge of the precise function of IL-2–activated NK cells in dogs with tumors may help to optimize new and therapeutically beneficial treatment strategies in canine and human cancer patients. Our findings suggest that the dog could also serve as a relevant large animal model for cancer immunotherapy with IL-2.
- 2 September 2004
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 54 (1) , 87-92
Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms
To investigate natural killer (NK) and lymphokine-activated killer (LAK) cell functions from 10 healthy dogs and 29 dogs with a variety of spontaneous neoplasms, large granular lymphocytes (LGLs) from blood samples were separated by a 58.5% Percoll density gradient. LGLs were stimulated with a low dose of recombinant human interleukin 2 (rhIL-2) for 7 days. Cytotoxicity of effector cells against the susceptible CTAC cell line was measured before and after stimulation. Compared with those before stimulation, the percentage of LGLs after stimulation with rhIL-2 was found to be significantly increased (PP<0.01) when compared with controls. Reduced cytotoxicity of rhIL-2–activated NK cells in dogs with tumors seems to be attributable to the presence of a diminished proliferative capacity of NK cells and a decreased ability of LAK cells to lyse target cells. Further knowledge of the precise function of IL-2–activated NK cells in dogs with tumors may help to optimize new and therapeutically beneficial treatment strategies in canine and human cancer patients. Our findings suggest that the dog could also serve as a relevant large animal model for cancer immunotherapy with IL-2.